Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: PTSC short volume hasn't changed much with heavier volume

Revenue consisting of software licenses and associated services relating to PDSG’s CDX product decreased from approximately $469,000 for the fiscal year ended May 31, 2011 to approximately $180,000 for the fiscal year ended May 31, 2012.

p.19

Share
New Message
Please login to post a reply